Companies risk losing up to 90% of the revenue of some of their biggest products to generic and biosimilar competition. Lifecycle management is a well-established tool to maximize sales throughout the commercial life of a product and retain market share as the patent expiration approaches.
Using our proprietary Peptelligence® drug delivery technology, Enteris BioPharma works with pharmaceutical partners to develop oral formulations of already marketed injectable products including peptides and BCS class II, III and IV small molecules, and by doing so, create a proprietary, patent-protected, oral reformulation of therapies. This makes Enteris the partner of choice for companies looking to revitalize a proven, but aging compound.
Interested in hearing more about the role Peptelligence® can play in life cycle management? Contact us today to learn how you can partner with Enteris BioPharma.CONTACT US